Reference : (19) F NMR in vivo spectroscopy reflects the effectiveness of perfusion - enhancing v...
Scientific journals : Article
Human health sciences : Oncology
Human health sciences : Radiology, nuclear medicine & imaging
(19) F NMR in vivo spectroscopy reflects the effectiveness of perfusion - enhancing vascular modifiers for improving gemcitabine chemotheraypy
Cron, Greg O. [> >]
Ansiaux []
MARTINIVE, Philippe mailto [Centre Hospitalier Universitaire de Liège - CHU > > Radiothérapie >]
Feron, O []
Gallez, B []
Beghein, N []
Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine
Wiley Liss, Inc.
Yes (verified by ORBi)
New York
[en] 19 F NMR ; gemcitabine ; in vivo spectroscopy ; Radiotherapy ; chemotherapy
[en] Laboratory of Biomedical Magnetic Resonance and Laboratory of Medicinal Chemistry and Radiopharmacy, Université Catholique de Louvain, UCL, Brussels, Belgium.

Nuclear magnetic resonance spectroscopy of fluorine-19 ((19)F NMR) has proven useful for evaluating kinetics of fluorinated chemotherapy drugs in tumors in vivo. This work investigated how three perfusion-enhancing vascular modifiers (BQ123, thalidomide, and Botulinum neurotoxin type A [BoNT-A]) would affect the chemotherapeutic efficacy of gemcitabine, a fluorinated drug widely used in human cancer treatment. Murine tumor growth experiments demonstrated that only BoNT-A showed a strong trend to enhance tumor growth inhibition by gemcitabine (1.7 days growth delay, P = 0.052, Student t-test). In accord with these results, (19)F NMR experiments showed that only BoNT-A increased significantly the uptake of gemcitabine in tumors (50% increase, P = 0.0008, Student t-test). Further experiments on gemcitabine kinetics (NMR vs time) and distribution ((19)F MRI) confirmed the uptake-enhancing properties of BoNT-A. The results of this study demonstrate that (19)F NMR can monitor modulation of the pharmacokinetics of fluorinated chemotherapy drugs in tumors. The results also show that (19)F NMR data can give a strong indication of the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy in murine tumors. (19)F NMR is a promising tool for preclinical evaluation of such vascular modifiers and may ultimately be used in the clinic to monitor how these modifiers affect chemotherapy. 2007 Wiley-Liss, Inc

PMID: 18050344 [PubMed - indexed for MEDLINE]
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Open access
Greg Cron NMR gemci.pdfAuthor postprint615.22 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.